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ABSTRACT
Introduction: Hypoglycemia is the most
common adverse effect of diabetes therapy,
particularly insulin treatment. Hypoglycemia
is associated with considerable clinical and
economic burden, and may be under-reported.
The aim of this study was to compare the
frequency of hypoglycemic events reported in
real-world settings with those reported in
clinical trials.
Methods: We conducted a structured literature
review in PubMed to identify hypoglycemic
event rates in patients with type 1 diabetes
mellitus (T1DM) and insulin-treated type 2
diabetes mellitus (T2DM) from real-world data
(RWD) and randomized controlled trials (RCTs).
The search was restricted to English language,
full-text publications from 2010 onwards,
reporting on treatment of T1DM or T2DM
with basal only, basal-bolus, or premix insulin.
Results: The final dataset included 30 studies (11
RWD studies and 19 RCTs). Six studies (RWD,
n= 2; RCT, n= 4) reported hypoglycemia event
rates in people with T1DM. For all reported
categories of hypoglycemia (severe, non-severe,
and nocturnal), rates were consistently higher in
RWD studies compared with RCTs. Twenty-five
studies (RWD, n= 10; RCT, n= 15) reported
hypoglycemia event rates in people with
insulin-treated T2DM. For T2DM basal-oral
therapy; the highest rates were observed in RWD
studies, although there was an overlap with RCT
rates. For basal-bolus therapy, there was
considerable between-study variability but higher
rates of severe and non-severe hypoglycemia were
generally observed in RWD studies. For T2DM
premix insulin, reported rates of hypoglycemia in
RWD studies and RCTs were similar.
Conclusion: We found that higher rates of
hypoglycemia are observed in real-world
settings compared with clinical trial settings,
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although there is a large degree of overlap. Due
to the inherent constraints of RCTs, they are
likely to underestimate the burden of
hypoglycemia in clinical practice. Further,
high-quality RWD are needed to determine a
more accurate incidence of hypoglycemia in
clinical practice.
Keywords: Clinical trial data; Diabetes
mellitus; Hypoglycemia; Hypoglycemia event
rates; Insulin; Nocturnal hypoglycemia; Real
world data; Severe hypoglycemia
INTRODUCTION
Diabetes is characterized by elevated blood
glucose levels (hyperglycemia) and is
associated with considerable morbidity and
mortality [1, 2]. Good glycemic control with
intensive treatment prevents or delays
microvascular complications, and reduces
cardiovascular and all-cause mortality [3, 4].
Therefore, a key clinical goal in the treatment
and management of diabetes is to achieve good
glycemic control with minimal hypoglycemia
or other adverse effects of treatment. The
recommended general glycemic target is a
glycated hemoglobin (HbA1c) level\7% [5–7].
The most common and highly feared adverse
effect of diabetes therapy, particularly insulin, is
hypoglycemia, which occurs when the plasma
glucose level becomes too low [8].
Hypoglycemia can occur suddenly and with
varying severity. Severe events are categorized
as those requiring the assistance of another
person, whereas non-severe events do not
require assistance [9–11]. Hypoglycemia has
been shown to negatively impact on quality of
life and productivity in the workplace [10, 12,
13]. Fear of hypoglycemia can have a behavioral
impact on diabetes management and metabolic
control. To avoid hypoglycemia, patients may
reduce or omit an insulin dose, which may
result in sub-optimal glucose control and
increase the risk of long-term complications
[14, 15].
Hypoglycemia is not only associated with
considerable cost to the individual in terms of
wellbeing, it also represents a substantial cost
burden to healthcare systems and society [16].
The total costs to the National Health Service, of
managing non-severe and severe hypoglycemia
in insulin-treated adults in the UK (population
64.1 million), were recently estimated at £172.1
million and £295.9 million per annum,
respectively [17].
It can be difficult to accurately determine the
frequency of hypoglycemic events due to
differences in methods of data collection and
the lack of a consistent clinical definition of
hypoglycemia. Non-severe hypoglycemia is
particularly underestimated as patients
infrequently report these events to their
physicians [18]. Randomized controlled trials
(RCTs) remain the most reliable source of
clinical evidence and are the gold standard for
demonstrating clinical efficacy. However, the
stringent constraints of a clinical trial setting,
and the selection of patients enrolled, may limit
the generalizability of RCTs to routine clinical
practice. Other sources of evidence, such as
real-world data (RWD), can be used to fill this
gap and complement the available RCT
evidence [19]. The use of RWD from sources
such as databases, patient medical chart reviews
and registries, and prospective and retrospective
studies is increasingly being recognized as a
valuable additional source of information to
inform decision making and improve patient
access to new drugs [19, 20]. While there is no
standardized definition of RWD, they are
generally defined as data that are not collected
in conventional RCTs [21]. RWD can provide
the evidence for a treatment outside the tight
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constraints of a clinical trial setting, for example
for patients excluded from trials, and patients
whose treatment is determined by clinical
practice rather than trial protocol. RWD can
both complement and build on the evidence
base established by RCTs and can be of
particular benefit in the study of large,
heterogeneous patient populations with
complex, chronic diseases such as diabetes [22].
The aim of the current study was to compare
the frequency of hypoglycemic events reported
in real-world settings with those reported in
clinical trials. A structured literature review was
conducted to identify hypoglycemic event rates
in patients with T1DM and T2DM using insulin
in real-world settings and RCTs. This study was
intended only as an observational analysis.
METHODS
A search was conducted in PubMed to identify
published literature that reported hypoglycemic
event rates in patients with T1DM and T2DM
treated with insulin. The search was conducted
on 9 December 2014 and was restricted to
English language, full-text publications from
2010 onwards. The date restriction was to
ensure that published hypoglycemia rates were
reflective of current clinical practice. Search
terms included diabetes mellitus, Type 1,
T1DM, insulin-dependent diabetes mellitus,
IDDM, Type 2, Type II, T2DM,
non-insulin-dependent diabetes mellitus,
NIDDM, glucose intolerance, hypoglycemia/
hypoglycaemia, randomized controlled trial,
real world, observational, and insulin. No
restrictions were placed on duration of
diabetes or country. For RCTs, the minimum
duration of studies of interest was 26 weeks, as
previous insulin titration studies have shown
that 26 weeks is sufficient for the majority of
patients to reach a stable HbA1c level [23, 24].
Due to the nature of data collection in RWD
studies, there was no restriction placed on
duration. Studies of interest were restricted to
those with total study populations C400
patients; this was to ensure a large enough
patient population for a reasonable estimation
of severe hypoglycemia rates, without too great
a restriction on the number of studies included
in the final dataset [25]. Only studies that
defined the diabetes population (i.e. T1DM or
T2DM) and the insulin regimen (basal insulin
only, basal-bolus, or premix) were included.
Eligibility criteria for the studies of interest are
shown in Table 1. The original eligibility criteria
for RWD studies specified any study reporting
RWD, with the exception of case studies.
However, a decision was made to exclude all
database studies upon assessment of full text.
This was because the majority of RWD database
studies are based on insurance claim databases,
where patients only tend to make a claim for
incidences of severe and emergency-related
hypoglycemic events, and thus, they do not
provide an accurate representation of overall
hypoglycemia in the real-world setting.
HbA1c target and mean end-of-trial HbA1c
level were recorded, if reported, due to the
relationship between HbA1c levels and
hypoglycemia risk.
Hypoglycemia Definition
For the purposes of this study, we considered
three categories of hypoglycemia—severe,
non-severe and nocturnal. Severe
hypoglycemic events were defined as those
that required the assistance of another person,
and non-severe events as those that could be
self-managed. Nocturnal events were simply
defined as those that occurred after bedtime
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and before the morning meal or insulin dose, to
encompass the various definitions of the
nocturnal period in the publications. A
nocturnal event could be severe or non-severe.
Although most studies reported severe
hypoglycemia separately, some studies
reported overall confirmed hypoglycemia
rather than non-severe hypoglycemia, which
could include all reported hypoglycemic events,
both severe and non-severe. If non-severe
hypoglycemia was not reported separately,
confirmed hypoglycemia was considered
representative of non-severe events for the
purpose of this analysis, as the contribution of
severe events had little impact on the overall
rate. A small number of studies reported
mutually exclusive groups of hypoglycemia;
non-severe daytime, non-severe nocturnal and
severe. Definitions of hypoglycemia used in
each study are recorded in Supplementary
Tables I–IV. Hypoglycemia event rates not
reported as episodes per patient year (PPY)
were converted to facilitate comparison.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
The original literature search identified 2171
potentially relevant studies. After removal of
duplicates, 1974 citations were screened on the
basis of title and abstract and any studies not
meeting the inclusion criteria were excluded
(n = 1750). A total of 224 full-text publications
were assessed for eligibility whereupon a further
194 studies were excluded. Reasons for
exclusion included: population B400; RCT
study duration \26 weeks; and hypoglycemia
event rates not reported. The final included
Table 1 Eligibility criteria for studies of interest
Eligibility criteria Description
Patient population Adults with a diagnosis of T1DM or T2DM
Receiving insulin treatment
Study design RCT of any design (blinded/open-label): C400 participants
Any study providing RWD with the exception of case studies: C400 participants
Study duration RCTs: C26 weeks (no restriction on duration was applied for RWD studies)
Intervention Insulin treatment
Basal only (irrespective of other combination oral therapies)
Basal-bolus
Premix
Use of OADs alone was not permitted
Outcomes of interest Hypoglycemia rates
Overall, severe, non-severe (mild/moderate), nocturnal
HbA1c glycated hemoglobin, NPH neutral protamine Hagedorn, OAD oral anti-diabetic drug, RCT randomized controlled
trial, RWD real-world data, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus
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dataset for analysis consisted of 30 studies, 11
RWD studies and 19 RCTs (Fig. 1).
The majority of RCTs identified in the
literature search had a treat-to-target design
whereby insulin doses are force-titrated to
achieve a pre-specified glycemic target [26]. In
general, HbA1c targets were consistent across
RCTs with targets of B6.5% or 7.0%
(Supplementary Tables I–IV).
Results are presented by diabetes population
(T1DM, T2DM on basal-oral therapy, T2DM on
basal-bolus therapy, and T2DM on premix
insulin), as rates of hypoglycemia vary
according to diabetes type/duration and
Fig. 1 Flow diagram of the literature search. Hypo hypo-
glycemia, NR not reported, RCT randomized controlled
trial, RWD real-world data. Other reasons included type
of diabetes not speciﬁed, insulin regimen not speciﬁed,
study data reported elsewhere as part of a main study
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insulin regimen. Studies will be represented
more than once if they report on more than
one diabetes population.
T1DM
Six studies (RWD, n = 2; RCT, n = 4) reported
hypoglycemia event rates in people with T1DM
[27–32]. For all reported categories of
hypoglycemia (severe, non-severe, and
nocturnal), rates were consistently higher in
the RWD studies than the RCTs (Table 2;
Supplementary Table I; rates are shown
graphically in Fig. 2). Non-severe rates were
91.0 and 136.8 episodes PPY in the two RWD
studies and 39.17–88.3 PPY in RCTs. Severe rates
ranged from 0.7 to 1.59 episodes PPY in RWD
studies versus (vs) 0.15–0.5 episodes PPY in
Table 2 Summary of hypoglycemia event rates in RWD studies versus RCTs in patients with T1DM and in patients with


















Non-severe/conﬁrmed 2 91.0–136.8 [30, 32] 3 39.17–88.3 [28, 29, 31]
Severe 2 0.7–1.59 [30, 32] 4 0.15–0.5 [27–29, 31]
Nocturnal 1 20.0 [32] 4 3.71–10.0 [27–29, 31]
T2DM: basal-oral regimen
Non-severe/conﬁrmed 7 0.224–35.3 [32–38] 10 0.286–16.4 [23, 39–47]
Severe 6 0.000–0.12 [32–37] 5 0.00–0.07 [39, 42,
44–46]
Nocturnal 6 0.277–13.4 [32, 34–38] 9 0.18–7.7 [23, 39,
41–47]
T2DM: basal-bolus regimen
Non-severe/conﬁrmed 3 2.95–38.9 [32, 37, 38] 4 9.28–26.6 [48–51]
Severe 2 0.00–0.2 [32, 37] 1 0.05-0.06 [49]
Nocturnal 3 0.42–8.5 [32, 37, 38] 3 1.39–10.34 [48, 49, 51]
T2DM: premix regimen
Non-severe/conﬁrmed 4 1.04–27.0 [32, 37, 52,
54]
5 7.08–20.8 [39, 48, 50,
51, 55]
Severe 4 0.00–0.2 [32, 37, 53,
54]
2 0.03–0.26 [39, 55]
Nocturnal 4 0.20–7.3 [32, 37, 52,
54]
3 2.5–8.15 [39, 48, 51]
RCT randomized controlled trial, RWD real-world data, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus
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Fig. 2 Ranges of hypoglycemia event rates in RWD studies
versus RCTs. Horizontal bars in i–iii show the ranges of
hypoglycemia rates as summarized in Table 2. RCT
randomized controlled trial, RWD real-world data,
T1DM type 1 diabetes mellitus, T2DM type 2 diabetes
mellitus
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RCTs. The only nocturnal rate reported in RWD
studies was 20.0 episodes PPY, vs 3.71–10.0
episodes PPY in RCTs. All four RCTs excluded
patients with severe hypoglycemia or
hypoglycemic unawareness. There was no
consistent pattern between end-of-trial HbA1c
levels and hypoglycemia rates; however, the
RCT by Mathieu et al. [31] had the highest rates
of hypoglycemia (across all categories) and the
lowest end-of-trial HbA1c levels, at week 26.
T2DM
Twenty-five studies (RWD, n = 10; RCT, n = 15)
reported hypoglycemia event rates in people
with insulin-treated T2DM. Hypoglycemia
event rates in RWD studies and RCTs of
patients with T2DM were compared according
to the insulin regimen, i.e. basal-oral,
basal-bolus, or premix regimen, as the risk of
hypoglycemia in patients with T2DM rises with
increasing duration of insulin therapy, and
increasing complexity of insulin regimen [8].
T2DM Basal-Oral Therapy
Seven RWD studies [32–38] and 10 RCTs [23,
39–47] reported hypoglycemia event rates in
people with insulin-treated T2DM receiving
basal-oral regimens (Table 2; Supplementary
Table II). There was variability in the rates of
hypoglycemia across both RWD studies and
RCTs for all hypoglycemia categories, and a
large degree of overlap between the RWD rates
and RCT rates. However, as for T1DM the
highest rates across all categories of
hypoglycemia were observed in the RWD
studies (Table 2; Fig. 2). Non-severe rates of
hypoglycemia ranged from 0.224 to 35.3
episodes PPY in RWD studies and from 0.286
to 16.4 episodes PPY in RCTs. Severe
hypoglycemia rates ranged from 0.00 to 0.12
episodes PPY in RWD studies and from 0.00 to
0.07 episodes PPY in RCTs. Nocturnal
confirmed event rates were 0.277–13.4
episodes PPY in RWD studies vs 0.18–7.7
episodes PPY in RCTs. Non-severe nocturnal
hypoglycemia rates were reported in two RWD
studies [32, 35]. Exclusion of patients with
recurrent severe hypoglycemia or a history of
severe hypoglycemia was reported in four of the
RCTs. Among RCTs, one RCT had the highest
rates of hypoglycemia in all hypoglycemia
categories, together with the lowest average
end-of-trial HbA1c (for patients who maintained
the HbA1c goal) [39]. However, no other trends
linking hypoglycemia rates and average
end-of-trial HbA1c levels were apparent.
T2DM Basal-Bolus Therapy
Three RWD studies [32, 37, 38] and four RCTs
[48–51] that reported hypoglycemia rates in
T2DM patients receiving basal-bolus insulin
regimens were identified in the literature
search (Table 2; Supplementary Table III). As
for T2DM basal-oral therapy, there was
variability in reported rates across
hypoglycemia categories and a large degree of
overlap between the RWD studies and RCTs.
The highest rates of severe and non-severe
hypoglycemia were observed in RWD studies,
whereas the highest rate of nocturnal
hypoglycemia was observed in an RCT
(Table 2; Fig. 2). Annual non-severe rates
ranged from 2.95 to 38.9 episodes PPY in RWD
studies vs 9.28–26.6 episodes PPY in RCTs.
Severe hypoglycemia rates ranged from 0.00 to
0.2 episodes PPY in RWD studies and from 0.05
to 0.06 episodes PPY in RCTs. Nocturnal
confirmed hypoglycemia event rates ranged
from 0.42 to 8.5 episodes PPY in RWD studies
vs 1.39–10.34 episodes PPY in RCTs. Three of
the RCTs excluded patients with a history of
severe hypoglycemia. In this patient
population, in the RCT setting, the highest
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rates of hypoglycemia for each category came
from different RCTs, and there was no
correlation with end-of-trial HbA1c levels.
Diurnal non-severe hypoglycemia rates were
reported in one RWD study [38] and one RCT
[49] and were almost threefold higher in the
RWD study. Non-severe nocturnal rates were
reported in one RWD study [32].
T2DM Premix Insulin
The search identified five RWD studies [32, 37,
52–54] and five RCTs [39, 48, 50, 51, 55] that
reported hypoglycemia event rates for T2DM
patients receiving a premixed insulin regimen
(Table 2; Supplementary Table IV).
Hypoglycemia event rates were variable across
studies reporting premixed insulin regimens,
and the range observed across RWD studies was
very similar to that observed in RCTs (Table 2;
Fig. 2). Non-severe hypoglycemia event rates
ranged from 1.04 to 27.0 episodes PPY in RWD
studies and from 7.08 to 20.8 episodes PPY in
RCTs. Annual rates for severe hypoglycemia in
RWD studies ranged from 0.00 to 0.2 episodes
PPY compared with 0.03 and 0.26 episodes PPY
in two RCTs. Annual rates of nocturnal
confirmed hypoglycemia were 0.20–7.3
episodes PPY in RWD studies vs 2.5–8.15
episodes PPY in RCTs. Three of the RCTs
excluded patients with a history of severe
hypoglycemia.
DISCUSSION
Although the results from large-scale RCTs have
conventionally been used to inform clinical
practice and reimbursement decisions, RWD are
now being recognized as a valuable additional
tool to inform current practice and future
research and development [19]. Advantages of
clinical trials include the prospective design,
pre-specified outcomes, randomization,
blinding and control groups, all of which can
contribute to the generation of solid evidence
under carefully controlled conditions. However,
the extrapolation of results from these studies
into clinical practice is challenging and may not
be fully representative of a general diabetes
population. Clinical trials of diabetes
populations usually exclude patients with
severe hypoglycemia, recurrent episodes of
hypoglycemia or hypoglycemia unawareness,
and the true incidence of hypoglycemia may be
underestimated. Patients with renal dysfunction
or elderly frail patients may also be
under-represented in clinical trials. Diabetes
patients with renal dysfunction are at an
increased risk of hypoglycemia as many
antidiabetic drugs are renally excreted [56].
Similarly, older ([75 years) people may have a
tendency toward hypoglycemia due to
malnutrition and comorbidities [57]. In
addition, patients enrolled in RCTs are usually
subjected to more intensive monitoring and
support than patients in routine clinical practice.
There are well documented limitations of
RWD, such as the potential for bias with
non-randomized data and inconsistent data
collection. However, guidelines have been
developed to provide more uniformity for
such studies [58] and the value of
observational research is being increasingly
recognized. Real-world data are essential for
informed reimbursement decisions and
different study designs can provide relevant
information in different situations [21].
Although RCTs remain the gold standard for
demonstrating clinical efficacy in restricted trial
setting, other study designs can contribute to
the comprehensive evidence base required for
healthcare decision makers.
This study compared the annual
hypoglycemia event rates of insulin-treated
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patients with T1DM and T2DM in studies
conducted in a real-world setting with those
reported in a clinical trial setting.
In patients with T1DM, for all reported
categories of hypoglycemia (severe,
non-severe, and nocturnal), rates were higher
in the RWD studies than the RCTs, with no
overlap in rates between RCT and RWD settings.
The two RWD studies with the highest rates of
hypoglycemia were specifically designed to
investigate hypoglycemia.
The rates of all categories of hypoglycemia in
patients with T2DM were lower than those
observed in patients with T1DM, as would be
expected. In patients with T2DM receiving a
basal-oral therapy regimen, there was overlap in
reported hypoglycemia rates between RCTs and
RWD studies; however, the highest rates of
hypoglycemia, for all categories, were observed
in a real-world setting. The RWD study with the
lowest reported hypoglycemia rates recorded
hypoglycemic events as adverse drug reactions
only, rather than a pre-defined outcome [33].
The RWD study [32] that reported higher rates
was a retrospective study specifically designed
to investigate the frequency of non-severe and
severe hypoglycemia in patients with diabetes
in seven European countries [32]. As this study
was designed to record hypoglycemic events, it
is more likely to be an accurate reflection of the
frequency of hypoglycemia in patients with
diabetes.
In T2DM patients receiving a basal-bolus
insulin regimen, the highest rates of severe and
non-severe hypoglycemiawere observed in RWD
studies, whereas the highest rate of nocturnal
hypoglycemiawas observed in anRCT. Although
again, there was a large degree of overlap in
reported rates between the RWD studies and the
RCTs. Only one of the five RCTs in this group
reported the rate of severe hypoglycemia, the
remainder simply reported number of patients
who experienced a severe event; this is likely due
to the low number of severe events in these
studies. The higher rate of nocturnal
hypoglycemia in the RCTs was driven by one
study, an insulin intensification study [48].
With respect to studies reporting premix
regimens in patients with T2DM, annual rates
of hypoglycemic events were variable across all
included studies, and the range was similar for
RWD studies and RCTs.
For the purposes of this study, we considered
three categories of hypoglycemia—severe,
non-severe and nocturnal. However, there was
inconsistency in the definitions of
hypoglycemia between individual studies. For
example, some RCTs defined confirmed
hypoglycemic events as a blood glucose level
\3.1 mmol/L (RCTs, n = 14; RWD, n = 7) and in
other studies, a blood glucose level\3.9 mmol/
L with or without symptoms (RCTs, n = 4;
RWD, n = 2) was considered a confirmed or
mild/moderate event. Although the American
Diabetes Association (ADA) definition of
hypoglycemia is a blood glucose concentration
\3.9 mmol/L [9], there is no consensus
definition of a threshold level at which
hypoglycemia is diagnosed; thresholds from
\3.9 to \3.0 mmol/L have also been defined
[18]. Blood glucose levels often fall below
3.9 mmol/L in healthy individuals; hence,
levels of 3.5–4.0 mmol/L are unlikely to be of
clinical significance [18, 59]. Many RWD studies
defined non-severe events as self-treated, with
or without a blood glucose measurement.
Furthermore, many studies reported confirmed
hypoglycemia, which included both severe and
non-severe events, and in some cases nocturnal
hypoglycemia. Thus, mutually exclusive groups
could not be defined. We saw no obvious
patterns between hypoglycemia definition and
event rates in our review, in that the rates were
not higher in those studies that used the higher
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blood glucose threshold of \3.9 mmol/L;
nevertheless, these caveats should be
considered when interpreting these data. It is
also important to consider HbA1c targets as
more stringent targets may explain higher
hypoglycemia event rates.
Severe hypoglycemia by its very nature
carries the risk of injury and can even be
life-threatening to a patient with diabetes if
not managed promptly [60]. Thus, it is
considered an important and dangerous
complication of diabetes. Although non-severe
hypoglycemia occurs more frequently than
severe hypoglycemia in both T1DM and
T2DM, the incidence and importance of
non-severe hypoglycemia are frequently
underestimated. As many non-severe
hypoglycemic events can be asymptomatic,
they may go unnoticed by the patient [61]. In
addition, some patients may not consider a
non-severe event significant enough to be
reported to their treating physician [32]. It is
therefore likely that many incidences of
non-severe hypoglycemia go unreported in the
real world. The RWD study by Ostenson et al.
reported that 65% of patients with T1DM and
50–59% of patients with T2DM either rarely or
never reported their hypoglycemia events to
their treating physician [32]. Some patients may
refrain from disclosing the frequency or severity
of their hypoglycemia for fear of losing their job
or driving license [62]. Others may deliberately
under-report events to their physician in case
they are perceived as being unable to control
their diabetes [18]. Episodes of nocturnal
hypoglycemia may also have been
under-reported in some studies as these events
may go unnoticed by patients and their
families. Hypoglycemia unawareness is the
failure to recognize the onset of hypoglycemia
or the complete absence of any warning
symptoms [9]. This can also result in lower
reported rates of hypoglycemia. Recurrent
episodes of hypoglycemia increase the risk for
the development of hypoglycemia unawareness
[60]. Unless a study has been designed to record
all categories of hypoglycemic events, it is likely
that hypoglycemia event rates will be
under-reported. A final consideration is that
studies utilizing self-reporting of hypoglycemic
events may be subject to recall bias.
When assessing full-text citations for
potential inclusion in the current study, it was
observed that the majority of studies that did
report hypoglycemia incidence only reported
the proportion of patients experiencing the
event rather than actual event rates. Studies
that report only the percentages of patients
experiencing a hypoglycemic event cannot be
used to estimate the true incidence of
hypoglycemia as they do not provide any
information regarding the actual frequencies
of the events themselves. While there is no
standard convention for the reporting of
hypoglycemia events in clinical studies, the
ADA Workgroup on Hypoglycemia
recommends that diabetes studies report both
hypoglycemia event rates and the proportion of
patients experiencing the event [9].
It is also important to consider whether
hypoglycemia is reported as a primary
outcome in the study. RCTs often only report
hypoglycemic events when they occur as
adverse reactions to the study drug under
investigation rather than as a primary
outcome. Non-severe hypoglycemic events are
often not recorded, making it difficult to
estimate the true incidence of hypoglycemia
in a trial population.
With respect to limitations of the data, this
study was intended only as an observational
analysis and focused on RCTs and RWD studies
that reported the annual frequencies of
hypoglycemia events in patients with T1DM
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and T2DM. No formal statistical analysis of the
data was conducted. The study was not
designed to determine average hypoglycemia
event rates in populations with diabetes, but
rather to compare hypoglycemia event ranges
reported in real-world and clinical trial settings.
In addition, during the literature search, no
restrictions were placed on the duration of
diabetes, intensity of insulin regimens, or
consideration of the duration of insulin
therapy, all of which have been shown to
impact the frequency of hypoglycemia in
patients with diabetes. For example, the UK
Hypoglycaemia Study Group reported that
patients with [15 years duration of T1DM
experienced higher rates of severe
hypoglycemia compared with patients with
\5 years duration of T1DM [8]. The study also
reported that longer duration of insulin
treatment ([5 years) was associated with
increased rates of mild hypoglycemia in T2DM
patients compared with those with shorter
duration of insulin treatment [8].
It should also be noted that study design and
how the data were collected could influence the
results. For example, a retrospective analysis is
likely to underestimate the true incidence of
hypoglycemic events, compared with a
prospective study. Similarly, there might be
differences in results depending on whether
the data were derived from patient diaries, or
whether they were based on the results of
continuous glucose monitoring.
CONCLUSION
In summary, a comparison of annual
hypoglycemia event rates in patients with
diabetes receiving insulin treatment showed
that in patients with T1DM and T2DM
(basal-oral and basal-bolus regimens) higher
rates of hypoglycemia are observed in
real-world settings compared with clinical trial
settings, although there is a large degree of
overlap in T2DM. Due to the rigorous restraints
of RCT study designs, it is difficult to accurately
estimate the frequency of hypoglycemia in
diabetes. Consequently, the use of
hypoglycemia data from RCTs of
insulin-treated patients with diabetes may not
be an accurate reflection of the true burden of
hypoglycemia in clinical practice. There is
clearly a need for further high-quality RWD
studies to confirm the findings of the current
review and to more accurately determine the
rates of hypoglycemia in the real world.
Observational studies of diabetes conducted in
a real-world environment can provide valuable
data regarding the use of a drug in clinical
practice as treatment is monitored under
real-life conditions rather than under the
stringent restraints of an RCT. Supplementing
efficacy data generated from RCTs with data
collected in real-world settings can further
demonstrate the value of new medicinal
products and ultimately improve healthcare
delivery to the patient.
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